INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Innoviva, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$21.08+0.30 (+1.44%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- 5.2
- Dividend yield
- –
Innoviva, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Revenue | $236.48M | $241.73M | $238.85M | $311.65M | $391.87M | $326.79M | $261.02M | $261.00M | $214.12M | $132.68M | 57.5% | -2.2% |
| Net product sales | $172.13M | $97.49M | $60.62M | $19.69M | $0 | $0 | – | – | – | – | 41.8% | +76.6% |
| XACDURO | $74.39M | $21.07M | $2.00M | $0 | – | – | – | – | – | – | 18.1% | +253.1% |
| GIAPREZA | $73.61M | $55.04M | $41.29M | $14.21M | – | – | – | – | – | – | 17.9% | +33.7% |
| XERAVA [Member] | $23.52M | $21.39M | $17.32M | $5.48M | – | – | – | – | – | – | 5.7% | +10.0% |
| License and other revenue | $2.72M | $19.49M | $11.00M | $0 | – | – | – | – | – | – | 0.7% | -86.0% |
| ZEVTERA [Member] | $610.00K | $0 | $0 | – | – | – | – | – | – | – | 0.1% | – |
| Revenue from collaborative arrangements | – | – | – | $0 | $0 | $10.00M | $0 | $0 | $3.10M | $885.00K | – | – |
| License revenue | – | – | $11.00M | $0 | $0 | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Innoviva's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.